Abstract
Petr Kocis earned his Ph.D. in organic and medicinal chemistry at the Czechoslovak Academy of Sciences, Prague, Czechoslovakia. He did his postdoctoral research with Prof. Jack Baldwin, the University of Oxford, England and worked with the Oxford Enzyme Group. During the last two decades he has been involved in drug discovery research in cancer, immunodeficiencies, asthma and drug lead discovery at Hoechst-Marion-Roussell, Zeneca Pharmaceuticals and AstraZeneca, lately as Associate Director, Global Enabling Science & Technologies, and Principle Scientist II. Dr. Kocis is one of the pioneers of combinatorial chemistry field, he helped to build Selectides combinatorial chemistry and technology in Tucson, Arizona, in the early 90s. In the mid 90s he co-build the US Chemical Technologies group at Zeneca Pharmaceuticals and co-developed a novel combinatorial chemistry that was industrialized within the International Lead Drug Discovery as a part of modern medicinal chemistry. He is a recipient of the R & D Directors Award for Creativity and Innovation by Zeneca, and a recipient of the Henry Christian Award for Excellence in Research by Merck. He is on the editorial board of several journals including Drugs of the Future and on the Scientific Advisory Board of Cambridge Healthtech Institute. Dr. Kocis is the author or coauthor of numerous articles, book chapters and patents. His research interest is multidimensional challenges of drug discovery, modern medicinal and combinatorial chemistry, visualization and data mining.
Current Drug Discovery Technologies
Title: About Editor-in-Chief
Volume: 1 Issue: 1
Abstract: Petr Kocis earned his Ph.D. in organic and medicinal chemistry at the Czechoslovak Academy of Sciences, Prague, Czechoslovakia. He did his postdoctoral research with Prof. Jack Baldwin, the University of Oxford, England and worked with the Oxford Enzyme Group. During the last two decades he has been involved in drug discovery research in cancer, immunodeficiencies, asthma and drug lead discovery at Hoechst-Marion-Roussell, Zeneca Pharmaceuticals and AstraZeneca, lately as Associate Director, Global Enabling Science & Technologies, and Principle Scientist II. Dr. Kocis is one of the pioneers of combinatorial chemistry field, he helped to build Selectides combinatorial chemistry and technology in Tucson, Arizona, in the early 90s. In the mid 90s he co-build the US Chemical Technologies group at Zeneca Pharmaceuticals and co-developed a novel combinatorial chemistry that was industrialized within the International Lead Drug Discovery as a part of modern medicinal chemistry. He is a recipient of the R & D Directors Award for Creativity and Innovation by Zeneca, and a recipient of the Henry Christian Award for Excellence in Research by Merck. He is on the editorial board of several journals including Drugs of the Future and on the Scientific Advisory Board of Cambridge Healthtech Institute. Dr. Kocis is the author or coauthor of numerous articles, book chapters and patents. His research interest is multidimensional challenges of drug discovery, modern medicinal and combinatorial chemistry, visualization and data mining.
Export Options
About this article
Cite this article as:
About Editor-in-Chief, Current Drug Discovery Technologies 2004; 1 (1) . https://dx.doi.org/10.2174/1570163043484842
DOI https://dx.doi.org/10.2174/1570163043484842 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sao Paulo Research Conference on Molecular Medicine and Pharmacogenetics, A Joint Meeting with the IUPHAR Sub-Committee on Pharmacogenetics and the Brazilian Pharmacogenetics Network, Sao Paulo, Brazil, September 18-20, 2008
Current Pharmacogenomics and Personalized Medicine Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Endocrine, Metabolic & Immune Disorders - Drug Targets The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design Monoclonal Antibodies: A Review
Current Clinical Pharmacology Molecular Mechanisms of Respiratory Virus-Induced Asthma and COPD Exacerbations and Pneumonia
Current Medicinal Chemistry Neuropeptide Conversion to Bioactive Fragments - An Important Pathway in Neuromodulation
Current Protein & Peptide Science The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Mast Cell Stabilizers in the Treatment of Allergic Rhinitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Mitogen-Activated Protein Kinases for Asthma
Current Drug Targets Recent Advances in Asthma Genetics and Antiasthma Therapy
Current Respiratory Medicine Reviews Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Evaluation of Antimicrobial and Antioxidant Activities of Latex and Extracts of <i>Euphorbia monostyla</i>
Current Bioactive Compounds Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Current Pharmaceutical Design Recent Advances in the Design and Synthesis of Prednisolone and Methylprednisolone Conjugates
Current Pharmaceutical Design Evaluation of Oxidative Status with Exhaled Breath 8-isoprostane Levels in Patients with Hyperthyroidism
Endocrine, Metabolic & Immune Disorders - Drug Targets p38 MAP Kinase Inhibitors as Anti inflammatory Agents
Mini-Reviews in Medicinal Chemistry Cellular Players in Lung Fibrosis
Current Pharmaceutical Design Clinical Significance and Evaluation of Polysensitisation Using Skin Sensitisation Profiling in Atopic Dermatitis
Inflammation & Allergy - Drug Targets (Discontinued)